| Ytd | 50.73% | |
| 1y | 304.02% |
| Open | 159.00 | Prev Close | 154.93 | Low | 156.39 | High | 160.13 | Mkt Cap | 2.26B |
| Vol | 182.30K | Avg Vol | 261.67K | EPS | -4.83 | P/E | -32.66 | Forward P/E | -22.15 |
| Beta | -0.17 | Short Ratio | 8.17 | Inst. Own | 97.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 130.13 | 200-d Avg | 109.83 | 1yr Est | 229.60 |
Palvella Therapeutics (NASDAQ: PVLA) said it remains on track to complete its new drug application s
WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”
Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript
Palvella Therapeutics NASDAQ: PVLA said it remains on track to complete its new drug application sub
First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submit
Arete Wealth Advisors LLC purchased a new position in Palvella Therapeutics, Inc. (NASDAQ: PVLA) dur
US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guid